MA50030A - Traitement du cancer par stimulation de la production d'il-12 - Google Patents

Traitement du cancer par stimulation de la production d'il-12

Info

Publication number
MA50030A
MA50030A MA050030A MA50030A MA50030A MA 50030 A MA50030 A MA 50030A MA 050030 A MA050030 A MA 050030A MA 50030 A MA50030 A MA 50030A MA 50030 A MA50030 A MA 50030A
Authority
MA
Morocco
Prior art keywords
stimulating
production
cancer treatment
cancer
treatment
Prior art date
Application number
MA050030A
Other languages
English (en)
Inventor
Stephen Mark Anderton
Clare Louise Doris
David Festus Charles Moffat
Martin John Perry
Original Assignee
Macrophage Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrophage Pharma Ltd filed Critical Macrophage Pharma Ltd
Publication of MA50030A publication Critical patent/MA50030A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
MA050030A 2017-08-31 2018-08-30 Traitement du cancer par stimulation de la production d'il-12 MA50030A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1713975.9A GB201713975D0 (en) 2017-08-31 2017-08-31 Medical use

Publications (1)

Publication Number Publication Date
MA50030A true MA50030A (fr) 2020-07-08

Family

ID=60050569

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050030A MA50030A (fr) 2017-08-31 2018-08-30 Traitement du cancer par stimulation de la production d'il-12

Country Status (15)

Country Link
US (1) US11382902B2 (fr)
EP (1) EP3675851A1 (fr)
JP (1) JP2020536848A (fr)
KR (1) KR20200129086A (fr)
CN (1) CN111356457A (fr)
AU (1) AU2018326668A1 (fr)
BR (1) BR112020003033A2 (fr)
CA (1) CA3071550A1 (fr)
GB (1) GB201713975D0 (fr)
IL (1) IL272769A (fr)
MA (1) MA50030A (fr)
MX (1) MX2020001197A (fr)
RU (1) RU2020111355A (fr)
SG (1) SG11202000565VA (fr)
WO (1) WO2019043389A1 (fr)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
FR2790960B1 (fr) * 1999-03-15 2002-10-31 Pf Medicament Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
WO2003068746A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryle-urees en tant qu'inhibiteurs de kinase
BRPI0307351B8 (pt) 2002-02-12 2021-05-25 Smithkline Beecham Corp composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
CA2478936A1 (fr) 2002-03-14 2003-09-18 Bayer Healthcare Ag Aroylpyridinones monocycliques tenant lieu d'agents anti-inflammatoires
US20060079461A1 (en) * 2003-12-24 2006-04-13 Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase
US20090215800A1 (en) 2005-05-05 2009-08-27 Chroma Therapeutics Ltd Enzyme and Receptor Modulation
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
GB0608823D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
CN102942520B (zh) 2006-05-04 2015-03-04 色品疗法有限公司 p38 MAP激酶抑制剂
GB0608821D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
EA200900593A1 (ru) 2006-10-25 2010-06-30 Хрома Терапьютикс Лтд. Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
CA2668070A1 (fr) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates en tant qu'inhibiteurs de l'histone desacetylase
ATE524454T1 (de) 2006-11-01 2011-09-15 Chroma Therapeutics Ltd Inhibitoren von ikk-beta serinthreoninproteinkinase
CA2668338A1 (fr) 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. Inhibiteurs de la serine-threonine proteine kinase ikk-~
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
JP2011503042A (ja) 2007-11-07 2011-01-27 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤
ES2427892T3 (es) 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
EA201001694A1 (ru) 2008-04-23 2011-06-30 Хрома Терапьютикс Лтд. Ингибиторы ikk-бета серин-треонин протеинкиназ
GB0807451D0 (en) 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
MX2010011643A (es) 2008-04-26 2010-11-30 Chroma Therapeutics Ltd Tiofencarboxamidas sustituidas como inhibidores de la proteina cinasa ikk-beta serina, treonina.
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
GB201021467D0 (en) 2010-12-17 2011-02-02 Chroma Therapeutics Ltd Imaging agents
EP2768862A2 (fr) * 2011-10-21 2014-08-27 Transgene SA Modulation de l'activation des macrophages
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
PL3222616T3 (pl) 2012-10-17 2019-12-31 Macrophage Pharma Limited N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination

Also Published As

Publication number Publication date
US11382902B2 (en) 2022-07-12
EP3675851A1 (fr) 2020-07-08
CA3071550A1 (fr) 2019-03-07
RU2020111355A3 (fr) 2021-12-16
IL272769A (en) 2020-04-30
BR112020003033A2 (pt) 2020-08-04
CN111356457A (zh) 2020-06-30
GB201713975D0 (en) 2017-10-18
WO2019043389A1 (fr) 2019-03-07
KR20200129086A (ko) 2020-11-17
US20200360359A1 (en) 2020-11-19
JP2020536848A (ja) 2020-12-17
MX2020001197A (es) 2020-08-13
RU2020111355A (ru) 2021-09-30
AU2018326668A1 (en) 2020-02-20
SG11202000565VA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA50056A (fr) Procédés de traitement de tumeur
IL275543A (en) Intratubular methods for the treatment of breast disorders
PT3474841T (pt) Métodos de tratamento do cancro de mama ar+
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
PT3458610T (pt) Tratamento terapêutico de cancro da mama baseado no estado de c-maf
WO2015197193A3 (fr) Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies
MA46361A (fr) Traitement du cancer de la prostate
MA47408A (fr) Traitement du cancer
MA53553A (fr) Traitement post-chirurgical de la douleur
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
ZA201903003B (en) Treatment of neurological diseases
MA52627A (fr) Traitement du cancer
ZA201908539B (en) Method of treatment of cancer
MY195000A (en) Method for the treatment of neurological disease
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique
IL266917A (en) Methods for treating prolactin receptor-positive breast cancer
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
DK3576740T3 (da) Cancerbehandling
EP3606522C0 (fr) Nouveau traitement de maladies mitochondriales
MA54932A (fr) Traitement contre le cancer
IT201900016760A1 (it) Dispositivo per il trattamento radioterapico di malati oncologici
MA52738A (fr) Méthodes de traitement de l'arthrite psoriasique
GB201805100D0 (en) Treatment of sarcopenic diseases
MA50030A (fr) Traitement du cancer par stimulation de la production d'il-12